Traditional noninvasive diagnostic tools that are currently used in the clinic, such as creatinine and cystatin C–based eGFR measurements, urinalysis, urine sediment examination, urine protein quantification, and urine electrolyte measurement, lack the sensitivity and specificity to distinguish between the various underlying etiologies of AKI in patients with cancer. The gene discussed is CST3; the disease is acute kidney injury.